Literature DB >> 11070165

Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells.

C Krawczyk1, K Bachmaier, T Sasaki, R G Jones, S B Snapper, D Bouchard, I Kozieradzki, P S Ohashi, F W Alt, J M Penninger.   

Abstract

Stimulation of T cells via the antigen and costimulatory receptors leads to the organization of a supramolecular activation cluster called the immune synapse. We report that loss of the molecular adaptor Cbl-b in T cells frees antigen receptor-triggered receptor clustering, lipid raft aggregation, and sustained tyrosine phosphorylation from the requirement for CD28 costimulation. Introduction of the cbl-b mutation into a vav1-/- background relieved the functional defects of vav1-/- T cells and caused spontaneous autoimmunity. Wiscott Aldrich Syndrome protein (WASP) was found to be essential for deregulated proliferation and membrane receptor reorganization of cbl-b mutant T cells. Antigen receptor-triggered Ca2+ mobilization, cytokine production, and receptor clustering can be genetically uncoupled in cbl-b mutant T cells. Thus, Cbl-b functions as a negative regulator of receptor clustering and raft aggregation in T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070165     DOI: 10.1016/s1074-7613(00)00046-7

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  57 in total

1.  The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation.

Authors:  N Rao; A K Ghosh; S Ota; P Zhou; A L Reddi; K Hakezi; B K Druker; J Wu; H Band
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  Ubiquitylation-dependent negative regulation of WASp is essential for actin cytoskeleton dynamics.

Authors:  Barak Reicher; Noah Joseph; Ahuvit David; Maor H Pauker; Orly Perl; Mira Barda-Saad
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

3.  Rapid microtubule-dependent induction of neurite-like extensions in NIH 3T3 fibroblasts by inhibition of ROCK and Cbl.

Authors:  Robin M Scaife; Didier Job; Wallace Y Langdon
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

4.  Pleiotropic defects in TCR signaling in a Vav-1-null Jurkat T-cell line.

Authors:  Youjia Cao; Erin M Janssen; Andrew W Duncan; Amnon Altman; Daniel D Billadeau; Robert T Abraham
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

Review 5.  Cbl-b in T-cell activation.

Authors:  Magdalena Paolino; Josef M Penninger
Journal:  Semin Immunopathol       Date:  2010-02-21       Impact factor: 9.623

6.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 7.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

8.  Cbl-b differentially regulates activation-induced apoptosis in T helper 1 and T helper 2 cells.

Authors:  Allison Hanlon; Sihyug Jang; Padmini Salgame
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

9.  Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus.

Authors:  Elizabeth C Jury; Panagiotis S Kabouridis; Fabian Flores-Borja; Rizgar A Mageed; David A Isenberg
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction.

Authors:  Stéphanie M Pontier; Yann Percherancier; Ségolène Galandrin; Andreas Breit; Céline Galés; Michel Bouvier
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.